Biohaven announced that it received orphan medicinal product designation from the European Commission (EC) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA). Orphan Designation highlights the potential for taldefgrobep to deliver significant benefit for people with SMA and provides regulatory and commercial incentives including a reduction in regulatory fees associated with protocol reviews and scientific advice, along with an additional ten-years of market protection. Biohaven previously received fast track and orphan drug designation from the FDA for taldefgrobep in the treatment of SMA.
SMA is a rare, progressively debilitating motor neuron disease in which development and growth of muscle mass are compromised, resulting in progressive weakness and muscle atrophy, reduced motor function, impaired quality of life and often death. Inhibition of myostatin, a naturally occurring protein that limits skeletal muscle growth, an important process in healthy muscular development, is a promising therapeutic strategy for SMA.
Taldefgrobep has the potential to be a novel therapy to enhance muscle function in SMA by blocking myostatin, when used in combination with currently available disease modifying therapies that help preserve motor neurons. Taldefgrobep's novelty in a field of myostatin inhibitors is based on its unique, dual mechanism of action. It binds to myostatin to lower overall myostatin levels and also functions as a receptor antagonist, thereby blocking myostatin signaling in skeletal muscles.
Irfan Qureshi, MD, Chief Medical Officer, Biohaven commented, "We are delighted that the European Commission granted orphan drug designation for taldefgrobep alfa for the treatment of SMA. Children and adults living with SMA experience significant muscle weakness and functional impairments affecting their quality of daily life, and a substantial unmet medical need persists. We are excited about the potential for taldefgrobep alfa to improve the lives of patients and families affected by SMA."
As a leader in innovative trials addressing neurodegenerative diseases, Biohaven is currently enrolling a Phase 3 clinical trial of taldefgrobep in SMA: A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants with Spinal Muscular Atrophy (RESILIENT) (NCT05337553).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!